System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42933636 DOI: 10.1016/j.annonc.2026.10.095

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study.

Ann Oncol

Authors: C M Rudin, M-J Ahn, M Schuler, F H Blackhall, G Mountzios, T Yoshida, L Sun, B C Cho, A Lugini, S Arulananda, S R Punekar, P Rocha, L Paz-Ares, J Mazières, M Gümüş, U Demirci, S Huang, B Abidi, U Patil, B Zhu

Affiliations

  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; National Center for Tumor Diseases West, Essen, Germany.
  • Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
  • Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Medical Oncology Unit, Azienda Ospedaliera San Giovanni Addolorata Hospital, Rome, Italy.
  • Department of Medical Oncology, Monash Health, Clayton, Australia.
  • Perlmutter Cancer Center, NYU Langone Health, NY, USA.
  • Department of Medical Oncology, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
  • Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Istanbul Medeniyet University, Istanbul, Türkiye.
  • Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Türkiye.
  • Amgen Inc. Thousand Oaks, CA, USA.
  • Second Affiliated Hospital of Army Medical University, Chongqing, China.

Abstract

BACKGROUND

In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended follow-up in patients with small-cell lung cancer (SCLC).

PATIENTS AND METHODS

In this phase 3, open-label trial, patients with SCLC whose disease had progressed on or after platinum-based chemotherapy were randomized (1:1) to receive either tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression, unacceptable toxicity, or death. The primary endpoint was OS. Secondary endpoints included investigator-assessed PFS, objective response, disease control, duration of response per RECIST v1.1, PROs, and safety.

RESULTS

As of data cutoff (18 February 2026), median OS was 13.6 and 8.4 months with tarlatamab and chemotherapy, respectively (median follow-up, 23.3 and 22.8 months). Median PFS was 4.2 and 3.2 months, respectively (median follow-up, 22.2 and 21.9 months). Kaplan-Meier estimated OS rates at 12/24 months were 55.9%/30.3% with tarlatamab versus 39.0%/14.9% with chemotherapy; corresponding PFS rates at 12/24 months were 20.6%/14.2% versus 5.9%/2.3%. Objective response rate was 35.4% with tarlatamab, including six confirmed complete responses versus 20.4% with chemotherapy; at data cutoff, ongoing responses were observed in 31.1% (28/90) versus 3.8% (2/52) of responders, respectively. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Treatment-related adverse events led to treatment discontinuation in 3.2% versus 6.6%; grade ≥3 events decreased over time, with no serious TRAEs with onset ≥12 months. CRS and ICANS occurred early in treatment and were predominantly low grade.

CONCLUSIONS

With extended follow-up, tarlatamab continues to demonstrate sustained and durable clinical benefit and a favorable long-term tolerability profile versus chemotherapy, in patients with SCLC after first-line platinum-based chemotherapy, supporting its use as the standard of care in this setting.

MeSH

Cells, Lung, Safety, Neoplasms, Drug Therapy, Immunotherapy, Lung Neoplasms, Small Cell Lung Carcinoma, Therapeutics, Chemotherapy